In addition, in second-line treatment of some patients with refractory advanced HCC, regorafenib and cabozantinib were associated with longer OS compared to placebo, while in patients with AFP >400 ng/mL, regorafenib, cabozantinib and remolizumab were associated with longer PFS and OS compared to placebo (20, 21).Therefore, TACE combined with HAIC, targeted therapy, and immunotherapy may serve as a new treatment modality for patients with unresectable HCC. This evidence concerns the gene AFP and hepatocellular carcinoma.